Ann: June 2024 Quarterly Activities Report and Appendix 4C, page-3

The Company & The University Of Western Australia Knows There Is Massive Value In The Patentable MDMA-like Compounds, Hence They Have Patents At A National Filing Stage Worldwide…..A Massive Tick From Me, Many Deals Could & Will Be Struck Here $$$$

Great To See The Fully-funded Preclinical Screening Program For Pain ( PSPP ) For RX7 Is Currently Completing Tier 2 evaluations ( assessment of neurotoxicity and efficacy in acute to chronic pain models ) & Expected To Advance To Tier 3 ( disease-specific models ) in H2,2024. I Still Think This Could Be The Catalyst To A Multi Bagger Here…$$$$

Business As Usual With The Growth Plans For Advanced Treatment and Clinical Service Expansion, Although Currently Cash Burn But Company Making For Growth, With Future Buy Out…Take Over Potential.

A Win Win On All Fronts, As Far As I’m Concerned And Great To Get A Company Update…Which Has Been A Bit Lapse Of Late.

This Is Still Priced At Peanuts For The Monkey’s….What A Bargain!

Cheers